Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Faster, Cleaner, Better.

Pelthos Therapeutics Inc (PTHS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] by (Cboe BZX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]

Cash Flow for [[ item.sessionDateDisplayLong ]]

Fiscal Year End Date: 12/31

(Values in U.S. thousands)

	12-2025	12-2024	12-2023	12-2022	12-2021
Cash Flows From Operating Activities
Net Income	-43,319	-7,955	-7,381	-2,459	-595
Depreciation Amortization	2,618	692	188	140	N/A
Accounts receivable	-8,810	N/A	N/A	N/A	N/A
Accounts payable and accrued liabilities	1,356	1,179	N/A	N/A	N/A
Other Working Capital	-6,071	35	2,051	641	-756
Other Operating Activity	31,636	257	4,161	110	-242
Operating Cash Flow	$-22,590	$-5,792	$-981	$-1,567	$-1,593

Cash Flows From Investing Activities
PPE Investments	-99	N/A	N/A	N/A	N/A
Net Acquisitions	-5,137	N/A	N/A	N/A	N/A
Investing Cash Flow	$-5,236	$N/A	$N/A	$N/A	$N/A

Cash Flows From Financing Activities
Change In Short Term Borrowing	17,898	N/A	N/A	N/A	N/A
Debt Issued	28,077	536	767	400	N/A
Debt Repayment	-845	-215	N/A	N/A	N/A
Common Stock Issued	206	5,972	255	N/A	N/A
Common Stock Repurchased	N/A	-167	N/A	N/A	N/A
Other Financing Activity	0	83	0	1,222	1,593
Financing Cash Flow	$45,336	$6,209	$1,022	$1,622	$1,593

Beginning Cash Position	513	96	55	N/A	N/A
End Cash Position	18,023	513	96	55	N/A
Net Cash Flow	$17,510	$417	$41	$55	$N/A

Free Cash Flow
Operating Cash Flow	-22,590	-5,792	-981	-1,567	-1,593
Capital Expenditure	-99	N/A	N/A	N/A	N/A
Free Cash Flow	-22,689	-5,792	-981	-1,567	-1,593